Puma Biotechnology Inc Dossier
Qualitative Analysis
Business overview
Puma Biotechnology, Inc. (NASDAQ: PBYI) is a commercial-stage biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics to enhance cancer care. The company's primary commercial asset is NERLYNX® (neratinib), an oral tyrosine kinase inhibitor approved by the FDA for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, and in combination with capecitabine for advanced or metastatic HER2-positive breast cancer. Additionally, Puma is actively developing alisertib, an in-licensed selective small-molecule inhibitor of aurora kinase A, currently undergoing Phase II clinical trials (ALISCA™-Breast1 and ALISCA™-Lung1) targeting metastatic breast cancer and small cell lung cancer.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the clinical development of alisertib, an oral selective Aurora Kinase A inhibitor, through the Phase II ALISCA-Breast1 and ALISCA-Lung1 trials. The company is utilizing a biomarker-directed approach to identify patient subgroups that derive the greatest clinical benefit, aiming to optimize trial design and accelerate regulatory pathways.
Expected impact: Establishes a secondary clinical asset to diversify the company's portfolio beyond NERLYNX and address significant unmet needs in metastatic breast cancer and small cell lung cancer.
Optimizing the commercial performance of NERLYNX (neratinib) in the United States by implementing a dose escalation strategy to mitigate the primary side effect of diarrhea, thereby improving patient adherence and treatment duration.
Expected impact: Aims to drive sustained demand and stabilize net product sales, supporting the raised 2026 net product revenue guidance of $202 million to $206 million.
Fully repaying all outstanding debt obligations to eliminate interest expenses and financial overhang, thereby maximizing financial flexibility to fund clinical pipeline activities.
Expected impact: Reduced outstanding debt to zero, leaving the company debt-free and improving cash flow allocation efficiency for R&D.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Pierre Fabre holds exclusive rights to develop and commercialize NERLYNX (neratinib) within Europe, Turkey, the Middle East, Africa, and Greater China (mainland China, Taiwan, Hong Kong, and Macau). This partnership allows Puma to leverage Pierre Fabre's commercial infrastructure to access major international markets without establishing a direct sales force.
Terms: Under the amended agreement for Greater China, Puma received an upfront payment of $50 million and is eligible to receive up to $240 million in additional regulatory and sales-based milestones, alongside double-digit tiered royalties on net sales.
Pint Pharma is responsible for the commercialization and registration of NERLYNX in Latin America, expanding the drug's global footprint into key emerging markets.
Terms: Puma receives royalty payments based on net sales of NERLYNX in the licensed Latin American territories.